Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

Christophe Cellier; Gerd Bouma; Tom van Gils; Sherine Khater; Georgia Malamut; Laura Crespo; Pekka Collin; Peter H. R. Green; Sheila E. Crowe; Wayne Tsuji; Eric Butz; Nadine Cerf-Bensussan; Elizabeth Macintyre; Jane R. Parnes; Francisco Leon; Olivier Hermine; Chris J. Mulder; Keijo Viiri

doi:10.1016/s2468-1253(19)30265-1

Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

Christophe Cellier, Gerd Bouma, Tom van Gils, Sherine Khater, Georgia Malamut, Laura Crespo, Pekka Collin, Peter H. R. Green, Sheila E. Crowe, Wayne Tsuji, Eric Butz, Nadine Cerf-Bensussan, Elizabeth Macintyre, Jane R. Parnes, Francisco Leon, Olivier Hermine, Chris J. Mulder, Keijo Viiri

Research output: Contribution to journal › Article › Scientific › peer-review

64 Citations (Scopus)

Original language	English
Pages (from-to)	960-970
Journal	The Lancet Gastroenterology & Hepatology
Volume	4
Issue number	12
DOIs	https://doi.org/10.1016/s2468-1253(19)30265-1
Publication status	Published - 2019
Publication type	A1 Journal article-refereed

Publication forum classification

Publication forum level 1

Access to Document

10.1016/s2468-1253(19)30265-1

Cite this

Cellier, C., Bouma, G., van Gils, T., Khater, S., Malamut, G., Crespo, L., Collin, P., Green, P. H. R., Crowe, S. E., Tsuji, W., Butz, E., Cerf-Bensussan, N., Macintyre, E., Parnes, J. R., Leon, F., Hermine, O., Mulder, C. J., & Viiri, K. (2019). Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. The Lancet Gastroenterology & Hepatology, 4(12), 960-970. https://doi.org/10.1016/s2468-1253(19)30265-1

@article{7304adc82cf448b59ecffaaa2e36e8d2,

title = "Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study",

author = "Christophe Cellier and Gerd Bouma and {van Gils}, Tom and Sherine Khater and Georgia Malamut and Laura Crespo and Pekka Collin and Green, {Peter H. R.} and Crowe, {Sheila E.} and Wayne Tsuji and Eric Butz and Nadine Cerf-Bensussan and Elizabeth Macintyre and Parnes, {Jane R.} and Francisco Leon and Olivier Hermine and Mulder, {Chris J.} and Keijo Viiri",

year = "2019",

doi = "10.1016/s2468-1253(19)30265-1",

language = "English",

volume = "4",

pages = "960--970",

number = "12",

}

Cellier, C, Bouma, G, van Gils, T, Khater, S, Malamut, G, Crespo, L, Collin, P, Green, PHR, Crowe, SE, Tsuji, W, Butz, E, Cerf-Bensussan, N, Macintyre, E, Parnes, JR, Leon, F, Hermine, O, Mulder, CJ & Viiri, K 2019, 'Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study', The Lancet Gastroenterology & Hepatology, vol. 4, no. 12, pp. 960-970. https://doi.org/10.1016/s2468-1253(19)30265-1

Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. / Cellier, Christophe; Bouma, Gerd; van Gils, Tom et al.
In: The Lancet Gastroenterology & Hepatology, Vol. 4, No. 12, 2019, p. 960-970.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

AU - Cellier, Christophe

AU - Bouma, Gerd

AU - van Gils, Tom

AU - Khater, Sherine

AU - Malamut, Georgia

AU - Crespo, Laura

AU - Collin, Pekka

AU - Green, Peter H. R.

AU - Crowe, Sheila E.

AU - Tsuji, Wayne

AU - Butz, Eric

AU - Cerf-Bensussan, Nadine

AU - Macintyre, Elizabeth

AU - Parnes, Jane R.

AU - Leon, Francisco

AU - Hermine, Olivier

AU - Mulder, Chris J.

AU - Viiri, Keijo

PY - 2019

Y1 - 2019

U2 - 10.1016/s2468-1253(19)30265-1

DO - 10.1016/s2468-1253(19)30265-1

M3 - Article

SN - 2468-1253

VL - 4

SP - 960

EP - 970

JO - The Lancet Gastroenterology & Hepatology

JF - The Lancet Gastroenterology & Hepatology

IS - 12

ER -